57-57-8
Chemical Structure
Propiolactone
Synonym(s): β-propiolactone; 2-Oxetanone; Betaprone
- CAS No.: 57-57-8
- Formula:C3H4O2
- Molecular Weight:72.06
IUPAC Name: oxetan-2-one
InChIKey: VEZXCJBBBCKRPI-UHFFFAOYSA-N
SMILES: O=C1OCC1
Biological Activity: Propiolactone (β-propiolactone; 2-Oxetanone) is a viral chemical inactivator that causes the infectious inactivation of viruses. Propiolactone was co-incubated with SARS-CoV at a ratio of 1:1000 (v:v) and used as a bacteriostatic agent to formulate the BPL-inactivated influenza virus vaccine (Flu-BPL)[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Propiolactone | 99.36% | Propiolactone (β-propiolactone; 2-Oxetanone) is a viral chemical inactivator that causes the infectious inactivation of viruses. Propiolactone was co-incubated with SARS-CoV at a ratio of 1:1000 (v:v) and used as a bacteriostatic agent to formulate the BPL-inactivated influenza virus vaccine (Flu-BPL). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Propiolactone (Standard) | ≥98% | Propiolactone (Standard) is the analytical standard of Propiolactone. This product is intended for research and analytical applications. Propiolactone (β-propiolactone; 2-Oxetanone) is a viral chemical inactivator that causes the infectious inactivation of viruses. Propiolactone was co-incubated with SARS-CoV at a ratio of 1:1000 (v:v) and used as a bacteriostatic agent to formulate the BPL-inactivated influenza virus vaccine (Flu-BPL). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Roberts A, et al. Immunogenicity and protective efficacy in mice and hamsters of a β-propiolactone inactivated whole virus SARS-CoV vaccine. Viral Immunol. 2010 Oct;23(5):509-19 [Content Brief]
- [2]. Kulkarni R, et al. Anti-SARS-CoV-2 IgG antibody response among Indian COVID-19 patients using β-propiolactone-inactivated, whole virus-based indirect ELISA. J Virol Methods. 2021 Jan;287:113996. [Content Brief]